The Technology We Offer We can create cell lines producing the raw material for virtually any pharmaceutical product that may be required Serum has developed and patented a new and unique method for constructing synthetic strands of DNA which includes only the exact DNA coding points that we require without having to include any unwanted peripheral DNA material in our selected working strand. This means that we can create precisely designed recombinant proteins which are accurately tailored to our exact requirements for the production of genetic raw material to produce new, more effective recombinant pharmaceuticals. Our technology also gives us the ability to design and create chimeric (fused) molecules of DNA expressing the characteristics of two entirely different proteins in a single chain or even expressing only the active centers of the proteins. For example we can create a new, unique protein possessing the characteristics of both erythropoietin which increases red blood cell counts in humans and GM-CSF which increases white blood cell counts. Thus a new drug combining both these properties would be immensely valuable in the treatment of cancer patients undergoing chemotherapy for example. The Difference Between Our Chimeric Molecules And Other Fused Molecules All chimeric molecules that are being produced by present methods are using the total genome and not just specific DNA encoding regions. The most obvious disadvantage of this is mutations and when dealing with chimeric molecules this problem is amplified when using present systems since we are dealing with two genes instead of one. Using our technology we use only the specific DNA coding points that are relevant to the molecule we wish to create. This offers the same advantages as for the construction of single recombinant protein molecules which is the exclusion of unwanted, peripheral DNA coding that can adversely affect the proteins you wish to construct.Ê Using present state-of-the-art techniques, the successful construction of working fused molecules that can consistently achieve the intended results is virtually impossible. However using our technology we can create working chimeric protein molecules which consistently achieve the desired results with relative ease. Our technology also allows us to create new and more target specific recombinant pharmaceuticals with an increased and precise focus which until now could not be achieved. Our research shows that our proteins have a much greater biological activity (potency) per unit that anything presently available, and that the yield from them under normal production conditions is several times greater than current standards. This translates into more potent (superior quality) pharmaceutical raw material which can be produced in greater quantities under normal conditions, in other words, better quality products at lower production costs. Virtually all of the products derived from this are patentable and the ones that may not be will be better and cheaper than their competitors thus they will command the market anyway, so the overall commercial value of this is practically incalculable. Advantages Of Our Technology 1. It allows us to create virtually any recombinant protein we wish to make, including working complex chimeric molecules. We can do this on a scale and level that is impossible using any other present state-of-the-art methods. 2. We can design and create precisely tailored synthetic strands of DNA which can produce highly effective and versatile recombinant proteins. This greatly reduces the time and effort involved in producing the proteins themselves plus it virtually eliminates the risk of mutations since all unwanted DNA codons are excluded from our original working genetic material. 3. We can design chimeric (fused) DNA molecules which are far superior to any fused molecules presently being produced. This means we can design and create a new generation of totally unique and highly effective pharmaceuticals that has the action of two different drugs combined into a single product. 4. By using efficient synthetic strands of DNA to originally work with we no longer need to rely on natural strands of DNA containing the entire genome for our original working material. This means we can work on any protein at any time without the problem of acquiring natural DNA for it. For example using present state-of-the-art methods, human Follicle Stimulating Hormone (FSH) needs to be collected from the human pituitary gland immediately after death in order to be successfully used to create recombinant FSH. Using our method we no longer need to do this. 5. We can produce high yielding recombinant raw material with greater bioactivity levels that anything presently being produced. This offers substantial savings to pharmaceutical companied while at the same giving them extremely high grade raw material to work with so they can have a superior product at a reduced cost. 6. Because of our pure and high yielding raw material we can in some cases also achieve lower scale-up costs than those now associated with these procedures. Again this translates into faster production time and lower costs for pharmaceutical producers.
HOME || ABOUT US || OUR TECHNOLOGY || DNA ENGINEERING || IVF SERVICES || CONTACT US